PMID- 31334037 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2228-5652 (Print) IS - 2228-5660 (Electronic) IS - 2228-5652 (Linking) VI - 9 IP - 2 DP - 2019 TI - Aptamedicine: a new treatment modality in personalized cancer therapy. PG - 67-70 LID - 10.15171/bi.2019.09 [doi] AB - Aptamers ( Aps ) are short single-strand nucleic acids exhibiting unique 3D structure which facilitate their targeting potential against various cancer molecular markers ( CMMs ). Such features of Aps not only make them as suitable homing agents in targeted drug delivery systems (DDSs) but also candidate them as macromolecules that inhibit the interaction of the target ligand with other proteins. On the other hand, the conjugation of Aps with another therapeutic molecule such as antisense oligonucleotides (ASOs), siRNAs/miRNAs, Aps , toxins, chemotherapeutic agents, DNAzymes/Ribozymes provides hopeful strategy to eradicate the malignancies and overcome the off-target unwanted side effects. Such prominent features of Aps make them a promising treatment modality to overcome the tumor complexity and heterogeneity, which can be consequently applied for personalized therapy of cancer by using bispecific Ap-based therapeutics. FAU - Vandghanooni, Somayeh AU - Vandghanooni S AD - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Eskandani, Morteza AU - Eskandani M AD - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Barar, Jaleh AU - Barar J AUID- ORCID: 0000-0002-0105-919X AD - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Omidi, Yadollah AU - Omidi Y AUID- ORCID: 0000-0003-0067-2475 AD - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng PT - Editorial DEP - 20181130 PL - Iran TA - Bioimpacts JT - BioImpacts : BI JID - 101558125 PMC - PMC6637218 OTO - NOTNLM OT - Aptamedicine OT - Aptamer OT - Cancer therapy OT - Drug delivery systems OT - Nanomedicine OT - Personalized medicine EDAT- 2019/07/25 06:00 MHDA- 2019/07/25 06:01 PMCR- 2019/01/01 CRDT- 2019/07/24 06:00 PHST- 2018/09/05 00:00 [received] PHST- 2018/11/15 00:00 [accepted] PHST- 2019/07/24 06:00 [entrez] PHST- 2019/07/25 06:00 [pubmed] PHST- 2019/07/25 06:01 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - 10.15171/bi.2019.09 [doi] PST - ppublish SO - Bioimpacts. 2019;9(2):67-70. doi: 10.15171/bi.2019.09. Epub 2018 Nov 30.